Biocon's scale in biosimilars positions India as the global hub for affordable biologics, potentially transforming access to cancer and autoimmune treatments across developing Asia.
Biocon's scale in biosimilars positions India as the global hub for affordable biologics, potentially transforming access to cancer and autoimmune treatments across developing Asia.
World's largest pure-play biosimilars company with 20+ molecules
Commercial presence in 120+ countries
Annualized revenue of $2.1 billion
This integration significantly bolsters India's position as a global biosimilars manufacturing and export hub, benefiting the broader APAC supply chain. For emerging Asian markets like Indonesia, Vietnam, and the Philippines, Biocon's expanded scale promises increased access to affordable cancer and autoimmune treatments, potentially impacting local healthcare budgets and competitive dynamics for regional pharmaceutical players. Monitor potential regulatory shifts in these markets to accommodate accelerated biosimilar approvals.
Commercial presence in 120+ countries
Annualized revenue of $2.1 billion
Sign in to save notes on signals.
Sign In